

LISTING OF CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

21. (Currently amended) A composition for inducing an immune response in a subject, comprising ~~at least~~ two purified peptides wherein ~~at least~~ a first peptide comprises at least 10 contiguous amino acids of the amino acid sequence as set forth as SEQ ID NO: 8 and ~~at least~~ a second peptide comprises at least 10 contiguous amino acids of the amino acid sequence set forth as SEQ ID NO: 14.

23. (Currently amended) The composition of claim 21 wherein ~~at least a~~ the first peptide comprises at least 15 contiguous amino acids of the amino acid sequence set forth as SEQ ID NO: 8 and ~~at least a~~ the second peptide comprises at least 15 contiguous amino acids of the amino acid sequence set forth as SEQ ID NO: 14.

24. (Currently amended) The composition of claim 21 wherein ~~at least a~~ the first peptide comprises at least 20 contiguous amino acids of the amino acid sequence set forth as SEQ ID NO: 8 and ~~at least a~~ the second peptide comprises at least 20 contiguous amino acids of the amino acid sequence set forth as SEQ ID NO: 14.

25. (Currently amended) A composition for inducing an immune response comprising ~~at least~~ two purified peptides wherein ~~at least a~~ the first peptide comprises the amino acid sequence as set forth as SEQ ID NO: 8 and ~~at least a~~ the second peptide comprises the amino acid sequence set forth as SEQ ID NO: 14.

26. (Currently amended) A method of making a composition for inducing an immune response in a mammal comprising combining a pharmaceutically acceptable excipient with ~~at least~~ two purified peptides wherein ~~at least~~ a first peptide comprises the amino acid sequence as set forth as SEQ ID NO: 8 and ~~at least~~ a second peptide comprises the amino acid sequence set forth as SEQ ID NO: 14.

27. (Currently amended) A method of inducing an immune response in a subject, comprising administering a composition according to claim 21 to the subject, wherein the subject is a mammal.

28. (Currently amended) A method of inducing an immune response in a subject, comprising administering a composition according to claim 24 to the subject, wherein the subject is a mammal.

29. (Previously presented) The method of claim 26, wherein the mammal is a human.

30. (Previously presented) The method of claim 27, wherein the mammal is a human.

31. (Currently amended) A method of inducing an immune response in a subject, comprising administering a composition according to claim 23 to the subject, wherein the subject is a mammal.

32. (Previously presented) The method of claim 31, wherein the mammal is a human.

33. (Previously presented) The method of claim 28, wherein the mammal is a human.

34. (Currently amended) A method of inducing an immune response in a subject, comprising administering a composition according to claim 25 to the subject, wherein the subject is a mammal.

35. (Previously presented) The method of claim 34, wherein the mammal is a human.

36. (Currently amended) The composition of claim 21 wherein ~~at least a~~ the first peptide comprises at least 25 contiguous amino acids of the amino acid sequence set forth as SEQ ID NO: 8 and ~~at least a~~ the second peptide comprises at least 25 contiguous amino acids of the amino acid sequence set forth as SEQ ID NO: 14.

37. (Currently amended) A method of inducing an immune response in a subject, comprising administering a composition according to claim 36 to the subject, wherein the subject is a mammal.

38. (Previously presented) The method of claim 37, wherein the mammal is a human.

39. (Currently amended) The composition of claim 21 wherein ~~at least a~~ the first peptide comprises at least 30 contiguous amino acids of the amino acid sequence set forth as SEQ ID NO: 8 and ~~at least a~~ the second peptide comprises at least 30 contiguous amino acids of the amino acid sequence set forth as SEQ ID NO: 14.

40. (Currently amended) A method of inducing an immune response in a subject, comprising administering a composition according to claim 39 to the subject, wherein the subject is a mammal.

41. (Previously presented) The method of claim 40, wherein the mammal is a human.

42. (Currently amended) The composition of claim 21 wherein ~~at least a~~ the first peptide comprises at least 40 contiguous amino acids of the amino acid sequence set forth as SEQ ID NO: 8 and ~~at least a~~ the second peptide comprises at least 40 contiguous amino acids of the amino acid sequence set forth as SEQ ID NO: 14.

43. (Currently amended) A method of inducing an immune response in a subject, comprising administering a composition according to claim 42 to the subject, wherein the subject is a mammal.

44. (Previously presented) The method of claim 43, wherein the mammal is a human.

45. (Currently amended) The composition of claim 21 wherein ~~at least a~~ the first peptide

comprises at least 45 contiguous amino acids of the amino acid sequence set forth as SEQ ID NO: 8 and ~~at least a~~ the second peptide comprises at least 45 contiguous amino acids of the amino acid sequence set forth as SEQ ID NO: 14.

46. (Currently amended) A method of inducing an immune response in a subject, comprising administering a composition according to claim 45 to the subject, wherein the subject is a mammal.

47. (Previously presented) The method of claim 46, wherein the mammal is a human.

48. (Previously presented) A composition for inducing an immune response in a subject, comprising at least one purified peptide comprising at least 10 contiguous amino acids of the amino acid sequence set forth as SEQ ID NO: 14.

49. (Currently amended) A method of inducing an immune response in a subject, comprising administering a composition according to claim 48 to the subject, wherein the subject is a mammal.

50. (Previously presented) The method of claim 49, wherein the mammal is a human.

51. (Previously presented) The composition of claim 48 wherein the sequence of the at least one peptide comprises at least 15 contiguous amino acids of the amino acid sequence set forth as SEQ ID NO: 14.

52. (Currently amended) A method of inducing an immune response in a subject, comprising administering a composition according to claim 51 to the subject, wherein the subject is a mammal.

53. (Previously presented) The method of claim 52, wherein the mammal is a human.

54. (Previously presented) The composition of claim 48 wherein the sequence of the at least one peptide comprises at least 20 contiguous amino acids of the amino acid sequence set forth as SEQ ID NO: 14.

55. (Currently amended) A method of inducing an immune response in a subject, comprising administering a composition according to claim 54 to the subject, wherein the subject is a mammal.

56. (Previously presented) The method of claim 55, wherein the mammal is a human.

57. (Previously presented) A method of making a composition for inducing an immune response in a mammal comprising combining a pharmaceutically acceptable excipient with at least one purified peptide comprising at least 10 contiguous amino acid residues of the amino acid sequence set forth as SEQ ID NO: 14.

58. (New) A method of making a composition for inducing an immune response in a mammal, comprising combining a pharmaceutically acceptable excipient with a composition according to claim 21.

59. (New) The method of claim 58, wherein the mammal is a human.